
    
      This is a double-blind, placebo-controlled clinical trial study on 150 patients with a recent
      (less than 3 month) ischemic stroke. All patients will give either MLC601 (100 patients) or
      placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard medication of post
      stroke for 3 months. Motor improvement will be monitored using Fugl-Meyer Assessment FMA.
    
  